Carlsbad, CA, United States of America

Stephanie Marie Truhlar

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 5.2

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stephanie Marie Truhlar

Introduction

Stephanie Marie Truhlar is a prominent inventor based in Carlsbad, California. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of four patents to her name, her work is paving the way for advancements in cancer treatment and allergic disease management.

Latest Patents

Among her latest patents, Truhlar has developed bispecific antibodies targeting immune checkpoints. This invention relates to antibodies that antagonize human PD-1 and agonize human CD137, which may be useful for treating solid and hematological tumors, both alone and in combination with chemotherapy and ionizing radiation. Additionally, she has patented DNA molecules encoding anti-IL-33 antibodies. These antibodies bind and neutralize human IL-33 and are useful as agents for treating conditions associated with allergic diseases, including atopic dermatitis.

Career Highlights

Truhlar is currently employed at Eli Lilly and Company, where she continues to innovate and contribute to the field of medicine. Her work focuses on developing novel therapeutic solutions that address critical health challenges.

Collaborations

Some of her notable coworkers include Yiqing Feng and Robert Jan Benschop, who collaborate with her on various projects within the company.

Conclusion

Stephanie Marie Truhlar's innovative work in the field of biotechnology exemplifies the impact of dedicated inventors on healthcare advancements. Her contributions are vital in the ongoing fight against cancer and allergic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…